BioSyent (RX) Stock Price, News & Analysis

Company Overview

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: C$10.91 to C$11.25
• 50-Day Range: C$10.60 to C$11.45
• 52-Week Range: C$8.20 to C$11.49
• Volume: 1,806 shs
• Average Volume: 5,957 shs
• Market Capitalization: C$130.39 million
• P/E Ratio: 18.75
• Dividend Yield: 1.60%
• Price Target: N/A
• Consensus Rating: N/A

RX Stock Analysis - Frequently Asked Questions

How have RX shares performed this year?

BioSyent's stock was trading at C$9.22 at the beginning of the year. Since then, RX stock has increased by 21.9% and is now trading at C$11.24.
View the best growth stocks for 2024 here.

How were BioSyent's earnings last quarter?

BioSyent Inc. (CVE:RX) posted its quarterly earnings data on Monday, August, 26th. The company reported $0.13 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.13. The business had revenue of $8.95 million for the quarter, compared to the consensus estimate of $8.80 million. BioSyent had a net margin of 21.14% and a trailing twelve-month return on equity of 20.88%.

How do I buy shares of BioSyent?

Shares of RX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of BioSyent own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioSyent investors own include Aurora Cannabis (ACB), Astec Industries (ASTE), Bank of Nova Scotia (BNS), Carnival Co. & (CCL), Cisco Systems (CSCO), Devon Energy (DVN) and Ford Motor (F).

Company Calendar

• Last Earnings: 8/26/2024
• Today: 11/21/2024
• Next Earnings (Estimated): 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: CVE:RX
• CUSIP: N/A
• CIK: N/A
• Web: www.biosyent.com
• Phone: +1-905-2060013
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C$0.60
• Trailing P/E Ratio: 18.83
• Forward P/E Ratio: 16.27
• P/E Growth: N/A
• Net Income: C$7.15 million
• Net Margins: 21.14%
• Pretax Margin: N/A
• Return on Equity: 20.88%
• Return on Assets: 12.86%

Debt

• Debt-to-Equity Ratio: 3.19
• Current Ratio: 6.13
• Quick Ratio: 6.91

Sales & Book Value

• Annual Sales: C$33.82 million
• Price / Sales: 3.87
• Cash Flow: C$3.67 per share
• Price / Cash Flow: 3.07
• Book Value: C$3.06 per share
• Price / Book: 3.69

Miscellaneous

• Outstanding Shares: 11,590,000
• Free Float: N/A
• Market Cap: C$130.97 million
• Optionable: Not Optionable
• Beta: 0.93